The p16
INK4a (p16) tumor suppressor gene is frequently inactivated by homozygous deletion or methylation of the 5 CpG island in cell lines derived from human non-small-cell lung cancers. However, the frequency of dysfunction in primary tumors appears to be significantly lower than that in cell lines. This discordance could result from the occurrence or selection of p16 dysfunction during cell culture. Alternatively, techniques commonly used to examine tumors for genetic and epigenetic alterations may not be sensitive enough to detect all dysfunctions within the heterogeneous cell population present in primary tumors. If p16 inactivation plays a central role in development of non-small-cell lung cancer, then the frequency of gene inactivation in primary tumors should parallel that observed in cell lines. The present investigation addressed this issue in primary rat lung tumors and corresponding derived cell lines. A further goal was to determine whether the aberrant p16 gene methylation seen in human tumors is a conserved event in this animal model. The rat p16 gene was cloned and sequenced, and the predicted amino acid sequence of its product found to be 62% homologous to the amino acid sequence of the human analog. Homozygous deletion accounted for loss of p16 expression in 8 of 20 cell lines, while methylation of the CpG island extending throughout exon 1 was observed in 9 of 20 cell lines. 2-Deoxy-5-azacytidine treatment of cell lines with aberrant methylation restored gene expression. The methylated phenotype seen in cell lines showed an absolute correlation with detection of methylation in primary tumors. Aberrant methylation was also detected in four of eight primary tumors in which the derived cell line contained a deletion in p16. These results substantiate the primary tumor as the origin for dysfunction of the p16 gene and implicate CpG island methylation as the major mechanism for inactivating this gene in the rat lung tumors examined. Furthermore, rat lung cancer appears to be an excellent model in which to investigate the mechanisms of de novo gene methylation and the role of p16 dysfunction in the progression of neoplasia.
Inactivation of the p16 tumor suppressor gene on chromosome 9p21 has been detected in Ͼ70% of cell lines derived from human non-small-cell lung cancers (NSCLCs) (19, 37, 39) . The importance of p16 inactivation in disrupting control of the normal cell cycle lies within its regulatory role in the retinoblastoma (Rb) pathway. p16 is an inhibitor of the cyclindependent kinases 4 and 6, which bind cyclin D1 and phosphorylate the Rb gene (25, 46) . Thus, p16 contributes to the maintenance of Rb in the unphosphorylated state, which inhibits cell cycle progression. This regulation is lost if either p16 or Rb is inactivated. The reciprocal relationship between Rb alterations in small-cell lung cancer (13) and p16 alterations in NSCLC suggests that dysfunction within the Rb pathway could be a major target in the genesis of this disease (37) .
The predominant mechanisms for inactivation of the p16 gene in human tumors include homozygous deletion (19) and aberrant methylation of a CpG island which extends from the promoter region into exon 1 (33) . Both events occur at frequencies of 40 to 50% (7, 38) , while mutations are observed in Ͻ10% of cell lines (35, 42) . Despite the strong evidence for the tumor-suppressing function and frequent inactivation of p16 in cell lines derived from NSCLCs, a dominant role for the p16 gene in the genesis of primary NSCLCs has not been clearly substantiated due to a significantly lower frequency of dysfunction in primary tumors (7, 33, 36) . The discordance in frequency of inactivation between cell lines and primary tumors could result from the occurrence or selection of p16 dysfunction in cell culture. Alternatively, this difference in frequency may stem from a lack of sensitivity by the assays used to detect homozygous deletion (microsatellite markers) and methylation (Southern analysis) within tumors that may have heterogeneous cell populations for p16 dysfunction and may also be contaminated by normal tissue. Support for the latter hypothesis comes from immunohistochemical studies, which indicate a lack of p16 expression in 50% of primary NSCLCs examined (21, 43) . In addition, fluorescence in situ hybridization studies indicate that the percentage of primary tumor cells exhibiting loss of both alleles may often be Ͻ40% (47), a frequency that may go undetected by microsatellite assays.
The question of whether p16 inactivation arises within primary or cultured tumors is particularly important in light of the involvement of CpG island methylation in the development and progression of many human cancers (18, 22, 28) . CpG island hypermethylation has been identified within specific chromosome loci prior to allelic loss (29, 31) , and the expression of several tumor suppressor genes (14, 30, 48) , including p16 (12, 27, 33) , is silenced in tumors in association with aberrant methylation within the CpG island of the gene. However, aberrant CpG island methylation of tumor suppressor genes, including p16, is especially common in cultures of transformed cells (14, 30, 33, 48) . Therefore, it is critical to define the dynamics underlying the evolution of p16 gene hypermeth-ylation during tumorigenesis and its role in establishing cultures from primary cancers.
The present investigation addressed these issues by using a rat model for lung cancer in which the frequency and mechanism for inactivation of p16 can be determined in matched primary lung tumors and derived cell lines. In conjunction with cloning and sequencing of the rat p16 cDNA, these studies were facilitated by a new PCR method (15) , methylation-specific PCR (MSP), which readily detects methylation of p16 alleles in heterogeneous cell populations. The potential involvement of the p16 gene in rodent cancers has been suggested by the loss of heterozygosity on mouse chromosome 4 (8, 16) and by the monosomy of rat chromosome 5 (10), which have been observed in rodent tumors; these regions contain the alpha interferon gene cluster that is syntenic to human chromosome 9p21-22. In addition, deletion of p16 has been detected in cell lines derived from murine lung tumors (1) and rat kidney tumors (20) , and low expression has been observed in some primary murine lung tumors (1) .
Recently, a second protein, p19 ARF (p19), has been identified (40) that arises from the p16 gene sequence but is encoded by an alternate first exon (designated 1␤). Together with exon 1␤, the second and third exons of p16 are used to encode a protein, p19, that is unrelated to the amino acid sequence of p16 due to a frameshift but can also inhibit cell cycle progression (40) . Because deletion of the p16 gene or alterations within exon 1␤ would affect the function of p19, this transcript was also cloned and examined for inactivation.
MATERIALS AND METHODS
Cloning and sequencing. A 304-bp fragment containing portions of the first two exons of p16 was generated from cDNA prepared from normal lung tissue by reverse transcriptase PCR (RT-PCR) using primers based on the mouse sequence (39); this fragment was ligated into the TA cloning vector (Invitrogen, San Diego, Calif.) and sequenced with the Sequenase kit (United States Biochemicals, Cleveland, Ohio). With this sequence information, the remaining portions of the p16 and p19 messages were obtained by rapid amplification of cDNA ends (RACE) (5Ј and 3Ј RACE systems; Life Technologies, Gaithersburg, Md.) by using two rounds of nested PCR. The p19 cDNA fragments were generated from 5Ј RACE experiments in which the gene-specific antisense primers were located in the second exon. Although these primers were designed to amplify both p16 and p19, they produced no sequences matching mouse p16. The 5Ј end of the p16 cDNA was generated by locating the antisense primers in the exon 1 sequence, which is unique to p16. The 3Ј sequence was generated by using p16 exon 1 sense primers. RACE products were cloned into the TA vector. Three or more 5Ј RACE clones each for p16 and p19 were sequenced with the Sequenase kit, and two 3Ј RACE clones were cycle sequenced with an ABI automated sequencing system (Perkin-Elmer, Foster City, Calif.).
Tissue origins and exposures. The experiments described here were carried out in facilities fully accredited by the American Association for Accreditation of Laboratory Animal Care. Eighteen primary rat lung tumors (T1 through T18) and corresponding cell lines (CL1 through CL18) were analyzed. Lung tumors were induced in F344/N rats exposured to either X rays (2), beryllium metal (34), cigarette smoke (9), plutonium-239 oxide (9), or cigarette smoke and plutonium-239 oxide (9) . Excluding X rays, all exposures were via inhalation. Separate portions of each lung tumor were fixed in 4% buffered paraformaldehyde for histological classification, frozen by immersion in liquid nitrogen, and used to establish a cell line. Cell lines were derived from tumor samples that were first xenografted in athymic nude mice and then established as in vitro epithelial cell lines. All derived cell lines produced tumors when reinjected into nude mice; the resulting histotypes were either adenocarcinoma (AC), squamous cell carcinoma (SCC), adenosquamous carcinoma (ASC), or pulmonary osteosarcoma (OS). The histotypes of these explants generally recapitulated that of the primary tumor. The exceptions were tumors of mixed histotype, i.e., ASC, in which the squamous phenotype was usually selected through initial propagation in the nude mouse. Spontaneously transformed cell lines were derived from type II lung epithelial cells isolated from an F344/N rat (CL 19 [24] ) and a Sprague-Dawley rat (CL 20 [23] ). Both of these cell lines produced ACs when injected into nude mice.
Tissue culture and nucleic acid isolation. Cell lines were grown in ITRI-1 medium (4) to 80% confluence, harvested by trypsinization, pelleted, and snap frozen in liquid nitrogen prior to isolation of RNA and DNA. Selected cell lines were grown to 20% confluence in ITRI-1 medium prior to demethylation of genomic DNA. Culture medium was replaced with ITRI-1 containing 1 M 2-deoxy-5-azacytidine (DAC) for 3 to 4 days to allow several cell doublings. Cells were then trypsinized and snap frozen. Total RNA was prepared with the Trizol reagent (Life Technologies), and DNA was isolated by standard phenol-chloroform extraction. Because tumor architecture was disrupted by freezing, the contaminating normal tissue was not removed by microdissection prior to isolation of DNA from primary tumors. However, the percent neoplastic cells estimated from the paraformaldehyde-fixed sections was Ն50% in all tumors analyzed.
p16 and p19 expression. First-strand cDNA was synthesized from 3 g of total RNA primed with random hexamers by using the Superscript Preamplification System (Life Technologies). To eliminate the possibility of false positives caused by residual genomic DNA, samples were treated with DNase (41), and primers were designed to cross exon splice junctions. Amplification products comprising a portion of exons 1 and 2 for p16, exons 1␤ and 2 for p19, and exons 5 through 8 of the glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) were generated from the cDNA template in parallel PCRs. Following cDNA synthesis, 10% of the product from each sample was used for each PCR. Three parallel PCRs were performed: p16 and p19 were amplified to assess expression, and GAPDH was amplified as a control for RNA integrity. Amplifications were carried out in 50-l reaction volumes for 35 cycles, each consisting of denaturation at 94ЊC for 1 min, annealing for 45 s, and extension at 72ЊC for 2 min (1 min for GAPDH). Primer pairs and annealing temperatures were as follows: for p16, 5Ј-CTTCACCAACGCCCCGAACAC-3Ј (sense) and 5Ј-CGGGAGAGGGTG GTGGGGTC-3Ј (antisense), 68ЊC; for p19, 5Ј-GCAGAGCATGGGTCGCAG GTTC-3Ј (sense) and the same antisense primer as that used for p16, 66ЊC; and for GAPDH, 5Ј-GGTGCTGAGTATGTCGTGGA-3Ј (sense) and 5Ј-GCCATG CCAGTGAGCTTCCC-3Ј (antisense), 59ЊC. The amounts of amplified products analyzed by electrophoresis were 10 l for p16 and p19 and 5 l for GAPDH. Each RT-PCR assay was repeated at least once for confirmation. PCR products generated from cDNA template were authenticated as p16 or p19 by direct sequencing.
Amplification of genomic DNA. p16 exon 1 and p19 exon 1␤ were amplified by PCR from tumor cell lines and primary tumors. After an initial 5-min denaturation at 94ЊC, amplifications were carried out for 35 cycles, each consisting of denaturation at 94ЊC for 45 s, annealing for 30 s, and extension at 72ЊC for 45 s. For p16, primers 5Ј-ATGGAGTCCTCTGCAGATAGA-3Ј (sense) and 5Ј-ATC GGGGGTACGACCGAAAGTGTT-3Ј (antisense) were used, with annealing at 58ЊC. For p19, primers 5Ј-GCAGAGCATGGGTCGCAGGTTC-3Ј (sense) and 5Ј-TGGTCCAGGATGTGGCTGCGGC-3Ј (antisense) were used, with annealing at 71ЊC. PCR products generated from genomic DNA were authenticated as p16 or p19 by direct sequencing. Exon 6/7 of the rat p53 gene was also amplified from each DNA sample as a control for DNA integrity, using conditions previously described (44) . Water blanks, in which no template DNA was added, were included in each experiment, and no PCR product was detected in these controls. Products were resolved by electrophoresis on 2.0% agarose gels.
Simple sequence repeat markers were amplified by PCR using 22 primer pairs dispersed (distance between markers ranged from 7 to 22 centimorgans) across chromosome 5 (Research Genetics, Huntsville, Ala.) under the following conditions: 16.5 pmol of each primer and 400 ng of genomic DNA, denaturation at 95ЊC for 5 min followed by 35 cycles, each consisting of denaturation at 95ЊC for 45 s, annealing at 55ЊC for 45 s, and extension at 72ЊC for 75 s. Products were analyzed on 6% nondenaturing polyacrylamide gels poststained in ethidium bromide.
Northern and Southern analysis. Twenty micrograms of total RNA from each sample was electrophoresed on 1% agarose formaldehyde gels, transferred to nylon membranes by capillary blotting, and cross-linked to the membrane by irradiation from a UV Stratalinker (Stratagene, La Jolla, Calif.). The p16 probe was limited to the first exon for specificity. The GAPDH probe was an RT-PCR product from a normal lung sample. Probes were gel purified and 32 P (Amersham, St. Louis, Mo.) labelled by random priming according to the manufacturer's instructions. After overnight hybridization at 65ЊC in 0.5 M Na 2 HPO 4 -7% sodium dodecyl sulfate, membranes were washed twice at 65ЊC in 40 mM Na 2 HPO 4 -1% sodium dodecyl sulfate, dried, and exposed to X-ray film with an intensifying screen. For Southern analysis, 5 g of DNA from each sample was digested with SacI or double-digested with SacI and HpaII and then electrophoresed on a 1% agarose gel. Membrane transfer and probe hybridizations were as described above.
Methylation-specific PCR. A new method, MSP, in which site-specific methylation can be determined even for CpG sites not located in methylation-sensitive restriction enzyme sites has been developed (15) . In MSP, genomic DNA is modified by treatment with sodium bisulfite, which converts all unmethylated cytosines to uracil and then to thymidine during the subsequent PCR step. Two sets of primers are used to amplify each region of interest: one pair recognizes a sequence in which CpG sites are unmethylated (modified by bisulfite to UpG), and the other recognizes a sequence in which CpG sites are methylated (unmodified by bisulfite). Primers are localized to regions containing frequent cytosines (to distinguish unmodified from modified DNA), and CpG pairs near the 3Ј end of the primers provide maximal discrimination in the PCR between methylated and unmethylated DNA. Annealing at the CpG sites located at the growing end strongly affects primer extension, and thus the methylation status of these sites is discerned.
Sodium bisulfite modification of DNA and PCR were performed by the tech-nique described by Herman et al. (15) . Briefly, 2-g aliquots of DNA were denatured with sodium hydroxide, treated with 3 M sodium bisulfite and 10 mM hydroquinone, purified with the Wizard DNA purification system (Promega, Madison, Wis.), and desulfonated with 0.3 M sodium hydroxide. Treated DNA was precipitated with ethanol and resuspended in 50 l of Tris-EDTA buffer.
PCR amplification was performed with approximately 150 ng of treated DNA as the template. Two sets of primers were designed at the same position, one set specific for DNA methylated at CpG sites and one specific for fully unmethylated DNA. After bisulfite treatment, double-stranded DNA is no longer complementary, so primer pairs were designed to amplify only the modified sense strand. Both pairs were used for each sample in separate reactions as follows: 94ЊC for 5 min; 35 cycles each of 94ЊC for 30 s, 51ЊC for 30 s, and 72ЊC for 30 s; and finally 72ЊC for 5 min. Negative control reactions were performed by using both sets of modified primers with untreated DNA, to confirm that unmodified DNA could not be amplified in the event of incomplete bisulfite reactions. One common 5Ј primer was paired with three different 3Ј primers to examine methylation status throughout exon 1 of the p16 gene. Primers are listed in Table 1 . Products were visualized on 2.0% agarose gels. Nucleotide sequence accession numbers. Accession numbers through GenBank for the p16 and p19 sequences are L81167 and L81168, respectively.
RESULTS
Sequences of rat p16 and p19 cDNAs. The sequence of the rat p16 cDNA is depicted in Fig. 1A . Its identity as p16 was supported by (i) its conservation within the ankyrin repeat regions of the gene, (ii) its 75% homology to the mouse p16 gene within the coding region and 88% homology within exon 1, and (iii) only 65% exon 1 homology and 63% overall homology to the mouse homolog of the closely related p15
INK4b
gene. The first exon of the rat p16 cDNA was defined as a CpG island based on established criteria (11) . The deduced amino acid sequence of the rat p16 product (Fig. 1B) was 75 and 62% homologous to mouse and human sequences, respectively.
The nucleotide sequence of the p19 transcript, formed by using the alternate first exon (exon 1␤), is shown in Fig. 1C . This exon was spliced onto the common exon 2 and produced a second open reading frame, with a size similar to that reported for mouse p19 (40) . The nucleotide sequence within the protein-coding region was 63% homologous to the mouse p19 gene. Exon 1␤ was also defined as a CpG island.
Expression of p16 and p19 in normal tissues and tumorderived cell lines. The p16 and p19 transcripts were not expressed at levels sufficient for detection by Northern blotting in any normal rat tissues (data not shown). Similar to expression in mouse and human tissues (39, 43) , p16 expression by RT-PCR was clearly present in rat spleen, liver, and lung and absent in kidney, colon, stomach, and brain (data not shown). Expression of p19 was detected in all tissues, corresponding to its ubiquitous expression in the mouse (40) . However, only trace levels of transcript were detected in kidney and colon (data not shown).
p16 mRNA was not detected in 11 of 20 tumor-derived cell lines, and the level of expression varied significantly in the 9 lines for which a transcript was observed (Fig. 2) . Only three cell lines (CL10, CL15, and CL19) had expression levels similar to that of normal lung ( Fig. 2; Table 2 ), while only a trace amount of p16 transcript was evident in three other cell lines (CL2, CL6, and CL9). Expression of p16 in the remaining three cell lines (CL4, CL7, and CL14) appeared to be higher than in normal lung. The relative intensities of product bands shown in Fig. 3 were reproduced in three separate experiments. Moreover, Northern analysis confirmed that p16 transcript from the three cell lines that appeared to be expressed most abundantly by RT-PCR analysis was also detected by hybridization with an exon 1-specific probe, while transcript from other cell lines was not detected (data not shown).
p19 mRNA was detected in 12 of 20 cell lines (Fig. 3) . Only a trace of p19 transcript was evident in two cell lines (CL8 and CL12). Expression in two cell lines (CL9 and CL10) approximated that observed in normal lung, while expression in the remaining cell lines appear to be increased.
Deletions of p16 exon 1 and p19 exon 1␤. The lack of p16 expression seen in 11 of 20 cell lines and only trace expression in 3 others could stem from gene deletion in some cells or from transcriptional silencing associated with methylation of the CpG island located within exon 1. If the structure of the rat p16 gene is similar to the structures of its mouse and human homologs (32, 39) , exon 1␤ could be located several kilobases upstream of exon 1, so that the p19 transcript could be lost as a result of the deletion of exon 1␤ and/or deletion of exon 2, which is shared by p16 and p19. Therefore, tumor cell lines were first analyzed by PCR for deletion of exons 1 and 1␤. Homozygous deletion of p16 exon 1 was detected in four cell lines ( Fig. 3; Table 2 ) which showed loss of p16 expression (CL8, CL11, CL16, and CL18). Four additional cell lines which had little or no p16 expression (CL1, CL9, CL10, and CL12) showed markedly reduced amplification products, suggestive of gene deletion ( Fig. 2 and 3) . These results were produced in a replicate experiment. In addition, Southern analysis of CL9 and CL10, which showed reduced amplification product, failed to detect hybridization signal in these samples, confirming results from the PCR-based assay (data not shown). The weak p16 amplification products in these cell lines were not due to DNA degradation, because the p53 control fragments were present at similar levels ( Fig. 3) among all cell lines. Because these cell lines are not clonal and were examined at an early passage (Ͻ10 passages), the weak p16 amplification products may reflect heterogeneity of the tumor cell populations in these cultures.
To determine whether the deletions could be physically mapped, the four cell lines with homogeneous p16 exon 1 deletions were analyzed for homozygous deletions of simple sequence repeat markers dispersed across rat chromosome 5. None of the 22 markers were deleted in any cell lines (data not shown), validating the interstitial nature of the deletion but not allowing the boundaries of the deletions to be defined.
Evidence for homozygous deletion of p19 exon 1␤ was detected in six cell lines (CL1, CL8, CL12, CL16, CL18, and CL20 [ Fig. 3] ). Two cell lines had complete loss of the exon (CL8 and CL16), while the remaining lines had reduced amplification products. Five of these cell lines also contained deletion of p16 exon 1, while this exon was present in CL20. All cell lines with evidence for homozygous deletion showed reduced or no expression of the p19 transcript compared to the other expressing cell lines (Fig. 2) . The exon 1␤ gene was a Primers designated BS anneal to unmethylated sequences, while primers designated BSM anneal to methylated sequences. Primer locations within exon 1 are indicated in Fig. 5 , with antisense primers 2, 3, and 4 located sequentially toward the 3Ј end of exon 1.
b Primer sequences reflect those required to amplify the sense strand of bisulfite-modified DNA. (Fig. 2 and 3) . Induction of p16 expression by DAC. To determine whether the reduced or absent p16 expression in cultures retaining a p16 gene might be due to gene methylation, eight cell lines were grown in the presence of DAC to achieve widespread demethylation of genomic DNA. Treatment of human cancer cell lines with DAC has been shown to result in demethylation of the p16 gene and reexpression of the p16 transcript (38) . RT-PCR analysis of treated cultures (Fig. 4) showed that p16 expression relative to that of GAPDH was induced, in contrast to untreated samples examined at the same passage. Two of the four cell lines that failed to express p19 but retained exon 1␤ were in the DAC-treated group (CL6 and CL13); neither line reexpressed p19 after treatment (data not shown), suggesting that methylation may not be a mechanism for silencing of this transcript. The deletion of exon 1␤ in CL20 did not prohibit expression of p16 after treatment with DAC, indicating that the deletion within this cell line was confined to exon 1␤ and did not include the p16 promoter.
p16 gene methylation in cell lines. To initially establish the concordance of the new MSP analysis with standard Southern analysis for determining DNA methylation status, two HpaII methylation-sensitive restriction sites were examined in the p16 CpG island (Fig. 5) by both techniques. Three of the cell lines selected (CL13, CL17, and CL20), which showed no expression of p16 but reexpressed the gene after DAC treatment, were densely methylated, as assessed by both techniques (Fig. 6) . CL7, which expressed the gene, had an unmethylated p16 gene, as did normal lung, as determined by Southern analysis. However, MSP indicated the presence of both methylated and unmethylated DNA in this cell line. The methylated PCR product in this sample was much less abundant than the product observed in cell lines in which methylation was evident by both assays (Fig. 6B) . These results are consistent with the greater sensitivity of MSP over Southern analysis (15) . Examination of CL15 by Southern analysis revealed the presense of 3.0-and 2.1-kb bands, indicating that some alleles were methylated at both HpaII sites while others were methylated at only one site. MSP analysis detected only methylated product in this cell line, as predicted, because the methylation-specific primer pair will amplify only template which has both HpaII sites methylated. Together, these results confirmed that the MSP assay accurately indicated the methylation state of the rat p16 gene at specific CpG sites.
MSP, using the primers located across the HpaII sites ( Fig.   FIG. 2 . RT-PCR analysis of p16 and p19 gene expression in rat lung tumor cell lines. Expression of GAPDH was determined as a control for RNA integrity. FIG. 3 . Detection of deletion of p16 exon 1 and p19 exon 1␤ in rat lung tumor cell lines by PCR. Amplification of p53 served as a control for DNA integrity. e This cell line had reduced p16 exon 1 amplification product compared to the p53 control amplimer. f SCC which showed an adenosquamous phenotype in the primary tumor. g Both methylated and unmethylated alleles were present in this cell line. h NA, not applicable.
5)
, was then used to analyze the methylation status of the 12 cell lines that had no evidence for p16 gene deletion ( Fig. 7 ; Table 2 ). Only three lines (CL4, CL7, and CL14) produced strong amplification by using the primers specific for unmethylated DNA; these cell lines had abundant expression of the p16 transcript. The remaining 9 cell lines with little or no p16 expression produced amplification product only with the methylation-specific primers, suggesting that the majority of the p16 exon 1 alleles in these samples were methylated. The density of methylation within the p16 gene was examined further by using two additional antisense primers with 3Ј ends located over CpG sites 2 and 3 or sites 4 and 5 (Fig. 5) . The distribution of methylated and unmethylated products among cell lines was identical to that observed with the first set of MSP primers (data not shown). Analysis of primary tumors for p16 deletion and methylation. The 18 primary rat lung tumors from which the tumor cell lines were established were analyzed by PCR for presence of p16 exon 1 and p19 exon 1␤. Both fragments were amplified from all primary tumor samples (data not shown). Primary lung tumors were then analyzed for methylation of p16 exon 1 by the MSP assay. Seventeen of 18 tumors produced amplimers from the unmethylated primer pairs, consistent with the presence of nonneoplastic tissue and/or neoplastic cells with unmethylated alleles. However, eight tumors also clearly produced amplimers by using the methylation-specific primers that examine the HpaII sites and CpG site 1, 2, and 3 ( Fig. 8 ; Table 2 ), indicating substantial levels of methylated CpG sites within p16 exon 1. The methylated primer pair that used the antisense primer with the 3Ј end located over CpG sites 4 and 5 ( Fig. 5 ) detected methylation not only within these eight tumors but also within an additional five tumors (Fig. 8) . Methylation of p16 was not detected by any of the MSP primer pairs (data not shown) in normal rat tissues that had been analyzed for gene expression, indicating that contaminating normal tissue could not account for the methylation detected in the primary tumors. All cell lines in which the p16 gene was extensively methylated were derived from tumors that also had methylation of this gene (Table 2) . Interestingly, of the eight cell lines with homozygous deletion of the p16 gene, four were derived from primary tumors that contained methylated p16 alleles (Table 2) . Methylation was detected in one tumor (T4) but not in its derived cell line. The phenotype of this tumor was adenosquamous and the derived cell line was an SCC, suggesting that the methylation detected in the primary tumor may have been localized to the adenomatous portion, which was not propagated in culture.
DISCUSSION
Results of this investigation clearly demonstrate that aberrant p16 CpG island methylation leading to the loss of p16 expression originates in primary tumors. Moreover, de novo methylation of the p16 exon 1 CpG island occurs frequently in primary lung tumors induced in rats. The mechanisms for p16 dysfunction in the rat lung tumor cell lines examined in this study parallel those seen in human cell lines (33, 37) , validating the rat as a model for studying the role of p16 in lung cancer.
The presence of aberrant p16 methylation in cell lines was strongly correlated with absent or low expression of the gene. Only CL7 which expressed p16 at high levels showed evidence for both methylated and unmethylated alleles, indicating heterogeneity within this cell line. The fact that trace or low levels of expression were detected in some cell lines with apparent Hybridization to the p16 exon 1 probe detected a 3.0-kb band in DNA digested with SacI. This band is retained following double digestion with SacI and HpaII if both HpaII sites are methylated, while no bands are visible if both sites are fully unmethylated (small fragments generated by restriction digestion are not retained on the gel). Partial methylation is indicated by the presence of a 2.1-kb band in DNA digested with SacI and HpaII. The same samples were also analyzed by MSP, using primers that encompass the HpaII sites and a CpG site 5Ј of the first HpaII site (primers BS-1/BSM-1 and BS-2/BSM-2) (Fig. 5 ). An amplification product of the primers specific for unmethylated sequence indicates the presence of unmethylated DNA at the HpaII sites, while the converse applies to the primers specific to methylated sequence.
FIG. 7. MSP analysis for p16 methylation in lung tumor cell lines. Bisulfitemodified DNA was amplified with primer pairs specific for unmethylated and methylated template as described for Fig. 6 complete methylation of exon 1 may indicate a lack of methylation at sites within the promoter region, leading to minimal levels of transcription. Although the methylated phenotype showed an absolute correlation between cell cultures and parent tumors, both methylated and unmethylated alleles were detected by the MSP procedure in most primary tumors. Estimating the extent to which this heterogeneity of methylation reflects contamination of the tumor by normal tissue or heterogeneity within the tumor cell population is difficult. In tumor 15, no unmethylated alleles were observed, and contamination of this tumor with normal cells was estimated to be only 2%. The fact that methylation was detected in tumors contaminated by up to 50% with normal tissue indicates that methylation must be extensive within many of these tumors. The studies described here did not attempt to show that methylation detected in primary tumors resulted in loss of p16 expression. Such experiments are difficult without specific antibodies that are reactive to rat p16 because tumor heterogeneity and contamination by normal tissues would render RT-PCR-based assays ineffective. However, several lines of evidence support the hypothesis that tumor cells harboring methylated p16 alleles would not express the transcript. First, Kratzke et al. (21) showed by immunohistochemistry that 47 of 100 human NSCLCs completely lacked p16 protein. Second, expression stemming from inactivation of only one p16 allele is unlikely given the fact that allelic loss is frequently detected in rodent and human tumors at the p16 locus (10, 16, 19, 20, 33 ). In the rare situation in which cell lines had retained both alleles, both were methylated (33) . This indicates a strong selection pressure for inactivating this gene. Finally, methylation of the p16 gene shown in cell lines from this study clearly resulted in a lack of expression.
It is clear that p16 inactivation via homozygous deletion is also frequent in rat cell lines, and this finding parallels that reported by Otterson et al. (38) in cell lines from human NSCLCs. Cell line deletions were too small to include loss of nearby microsatellite markers, and in one case the deletion was small enough to encompass p16 exon 1 but not p19 exon 1␤. This is also consistent with homozygous deletions of human p16, which in some tumors involved a region of only 170 kb (7) . Homozygous deletions of p16 were not detected in the matched primary tumors; however, this probably reflects cell heterogeneity stemming from contamination of tumor by normal tissue. In addition, fluorescence in situ hybridization studies indicate that when total deletion of p16 is detected, it often occurs in Ͻ40% of tumor cells from NSCLCs (47), a frequency which would have been undetected in our study. Interestingly, CpG island methylation was detected in four of the eight primary tumors corresponding to the eight cell lines with evidence of gene deletion. Hypermethylation within CpG islands has been hypothesized to lead to changes in chromatin structure which may predispose the islands to genetic instability. For example, a previous study (31) with renal tumors demonstrated that regional hypermethylation on chromosome 17p, in an area subsequently shown to harbor a candidate tumor suppressor gene (30) , preceded allelic loss. Our results may indicate such a relationship between methylation and homozygous deletion of the p16 locus.
This study is the first to examine dysfunction of p19 in cell lines derived from lung tumors. The absence of methylation within p19 exon 1␤, an observation consistent with studies of human tumors (15a), and the lack of coordinate tissue-specific expression are further evidence that this gene is controlled by its own promoter (40) and that its regulation is independent and distinct from that of p16. A lack of p19 expression was observed in four cell lines in which exons 1␤, 2, and 3 were present. This effect could stem from mutations within exon 1␤ or the p19 promoter. Studies to define the mechanism for loss of expression and its effect on cellular phenotype may better define the role of this alternate transcript in normal cellular functions.
The frequency of p16 methylation observed in primary rat lung tumors (72%) surpasses the frequency of 26% obtained by Southern analysis in human lung tumors (33) . A similar frequency has also been observed in primary rat lung tumors induced by plutonium from which cell lines were not established (5a), indicating that the high frequency of aberrant methylation of p16 was not a function of selecting tumors for analysis from which cell lines were established in culture. This difference may be due in part to the greater capability of MSP analysis to detect methylation, but it could also reflect the fact that the majority of rat lung tumors examined were induced by radiation exposure. A recent study by Issa et al. (17) revealed a carcinogen-specific effect on methylation of the estrogen receptor gene in rat and human lung tumors. Specifically, a higher frequency of methylation was observed in lung tumors from individuals who had never smoked than in tumors from smokers and in rodent tumors induced by radiation than in rodent tumors induced by the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Alternatively, factors involved in initiating the spread of methylation through the p16 CpG island may differ between humans and rodents. Vertino et al. (45) demonstrated that CpG island loci differ in their inherent tendency to undergo de novo methylation.
The potential contributions of species and exposure differences to the frequency of CpG island methylation will remain elusive until events that lead to de novo methylation and the targeting of specific genes are clearly defined. Our rat model may be an excellent setting for such studies. Recent studies in our laboratory (3) have shown that carcinogen exposure can induce the activity of DNA methyltransferase, the enzyme responsible for methylation of CpG sites (6) . Moreover, this activity is induced selectively in the alveolar type II pneumocyte, the cell of origin for the resulting murine lung tumors (5), and is an early event in lung cancer evolution which increases during tumor progression. DNA methyltransferase activity is also elevated in rat and human lung tumors (5a). Overexpression of DNA methyltransferase in human fibroblasts has been associated with hypermethylation of promoter region CpG islands of some cancer-related genes (e.g., the estrogen receptor gene), while the p16 gene remains unmethylated in this setting (45) . However, these fibroblasts already have a functionally inactivated Rb gene due to simian virus 40 T antigen, and thus, there is no selective advantage for loss of p16. Effects on locus-specific factors such as Sp1 (26) may protect CpG islands from de novo methylation and could be required for initiating FIG. 8 . MSP analysis for p16 methylation in primary lung tumors. Bisulfitemodified DNA was amplified with the primer pairs (specific for unmethylated and methylated template) that encompassed CpG site 1 and both HpaII sites (top two panels) as described for Fig. 6 and with the methylation-specific primer (bottom panel) that encompassed CpG sites 4 and 5 (primer BSM-4) (Fig. 5). aberrant methylation within the p16 gene. Studies of p16 throughout tumor evolution in rodent carcinogenesis models should help identify factors important in aberrant methylation of this gene and define its role in the progression of neoplasia.
